163 related articles for article (PubMed ID: 18452853)
1. Erythropoietins should be used according to guidelines.
Aapro MS; Birgegård G; Bokemeyer C; Cornes P; Foubert J; Gascon P; Glaspy J; Hellström-Lindberg E; Link H; Ludwig H; Osterborg A; Repetto L; Soubeyran P
Lancet Oncol; 2008 May; 9(5):412-3. PubMed ID: 18452853
[No Abstract] [Full Text] [Related]
2. Erythropoietin: high profile, high scrutiny.
Crawford J
J Clin Oncol; 2007 Mar; 25(9):1021-3. PubMed ID: 17312331
[No Abstract] [Full Text] [Related]
3. New ASH/ASCO guidelines on the use of erythropoiesis-stimulating agents: a chorale amid cacophony.
Steensma DP
J Support Oncol; 2007; 5(10):471-3. PubMed ID: 18240668
[No Abstract] [Full Text] [Related]
4. Managing anemia: what do we do now?
Neumann ME
Nephrol News Issues; 2007 May; 21(6):50, 52. PubMed ID: 17518123
[No Abstract] [Full Text] [Related]
5. [Recent advances on the use of erythropoietin in oncology].
Spaëth D
Bull Cancer; 2006 May; 93(5):489-93. PubMed ID: 16777627
[TBL] [Abstract][Full Text] [Related]
6. Consensus on the Existence of Functional Erythropoietin Receptors on Cancer Cells.
Bennett CL; Lai SY; Sartor O; Georgantopoulos P; Hrushesky WJ; Henke M; Armitage JO
JAMA Oncol; 2016 Jan; 2(1):134-6. PubMed ID: 26606114
[No Abstract] [Full Text] [Related]
7. Darbepoetin alfa and history of thromboembolic events.
Ferretti G; Felici A; Cognetti F
J Clin Oncol; 2009 Nov; 27(33):e211; author reply e212. PubMed ID: 19858373
[No Abstract] [Full Text] [Related]
8. Comparative studies on erythropoietic agents.
Straus D
J Natl Compr Canc Netw; 2005 Nov; 3 Suppl 1():S46-9. PubMed ID: 16280113
[No Abstract] [Full Text] [Related]
9. Comment: Epoetin alfa versus darbepoetin alfa for cancer patients with treatment-related anemia.
Yang MC
Ann Pharmacother; 2006 May; 40(5):998-9; author reply 999. PubMed ID: 16670351
[No Abstract] [Full Text] [Related]
10. Epoetin: for better or for worse?
Lancet Oncol; 2004 Jan; 5(1):1. PubMed ID: 14700601
[No Abstract] [Full Text] [Related]
11. Epoetin alfa and darbepoetin alfa go head to head.
Steensma DP; Loprinzi CL
J Clin Oncol; 2006 May; 24(15):2233-6. PubMed ID: 16710021
[No Abstract] [Full Text] [Related]
12. New oversight put in place for physicians giving anemia drugs to patients with cancer.
Mitka M
JAMA; 2010 Apr; 303(14):1355-6. PubMed ID: 20388885
[No Abstract] [Full Text] [Related]
13. Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy.
Wauters I; Vansteenkiste J
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1383-90. PubMed ID: 23113603
[TBL] [Abstract][Full Text] [Related]
14. Erythropoietin, the FDA, and oncology.
Steinbrook R
N Engl J Med; 2007 Jun; 356(24):2448-51. PubMed ID: 17568025
[No Abstract] [Full Text] [Related]
15. ESAs further restricted, but debate continues.
Brower V
J Natl Cancer Inst; 2008 Oct; 100(19):1344-51. PubMed ID: 18812542
[No Abstract] [Full Text] [Related]
16. Erythropoietin-stimulating agents: new data yield new insights.
Zitella L
Oncology (Williston Park); 2007 Oct; 21(11 Suppl Nurse Ed):36-8. PubMed ID: 18154208
[No Abstract] [Full Text] [Related]
17. Utilizing quality of life as a factor in treatment choices for chemotherapy-induced anemia.
Koopman W; Iakiri S
J Support Oncol; 2005; 3(6 Suppl 4):20-1. PubMed ID: 16355554
[No Abstract] [Full Text] [Related]
18. FDA finalizes REMS program for ESAs; Amgen continues to study risks.
Brower V
J Natl Cancer Inst; 2010 May; 102(9):592-3. PubMed ID: 20421565
[No Abstract] [Full Text] [Related]
19. Cancer- and treatment-related anemia.
Rodgers GM; Cella D; Chanan-Khan A; Chesney C; Cleeland C; Coccia PF; Demetri GD; Djulbegovic B; Garst JL; Gore M; Kraut EH; Lin WC; Millenson M; Mock V; Reinke D; Rosenthal J; Sabbatini P
J Natl Compr Canc Netw; 2005 Nov; 3(6):772-89. PubMed ID: 16316613
[No Abstract] [Full Text] [Related]
20. Warning flags for erythropoiesis-stimulating agents and cancer-associated anemia.
Lappin TR; Maxwell AP; Johnston PG
Oncologist; 2007 Apr; 12(4):362-5. PubMed ID: 17470677
[No Abstract] [Full Text] [Related]
[Next] [New Search]
